Last Month in Nephrology

August 2018

After revolutionizing the management of hepatitis C, DAAs (Directly Acting Antivirals) are all set to expand the donor pool in deceased donor kidney transplantation.

Last Month in Nephrology

July 2018

In an RCT from Kolkata, Basu et al randomized 176 children aged 3 to 16 years with the corticosteroid-dependent nephrotic syndrome to receive either tacrolimus (along with tapering alternate-day prednisolone) for 12 months or a single course of rituximab (2 infusions of 375mg/m2).

Last Month in Nephrology

June 2018

In a primary cohort of 666 children and a validation cohort comprising of 333 children who underwent cardiac surgery with cardiopulmonary bypass, the incidence of AKI was higher among those with no acetaminophen exposure than among those with acetaminophen exposure.

Last Month in Nephrology

May 2018

“Among women with uncomplicated UTI, a 5-day course of nitrofurantoin compared with single-dose fosfomycin resulted in a significantly greater likelihood of clinical and microbiologic resolution at 28 days after therapy completion”


Month of March is always special with World Kidney Day celebrations

April 2018

On the occasion of World Kidney Day, MNG in collaboration with IMA arrranged CME in 3 locations. Over 700 GPs attended the program. The program involved each and every MNG member.

Last Month in Nephrology 

March 2018

In their monthly blog “last month in Nephrology” Dr. Tukaram Jamale and Dr. Vaibhav Keskar try to think aloud on the published evidence, and no way claim to be the final word which probably doesn’t exist in science.

From The Editorial Desk

February 2018

As we all know, the quest for knowledge is an eternal process. And this thought is something that has been inscribed deeply into our minds at the Mumbai Nephrology Group (MNG).We are always in a process of reinventing ourselves to continue to learn and spread the knowledge.

Last Month in Nephrology

January 2018

If you initiate dialysis a few hours earlier in the course of AKI-that essentially means dialyzing almost every AKI that needs nephro consult–you get almost everything that you will like to offer your critically ill patient with AKI: 15.4% absolute risk reduction in mortality.

Last Month in Nephrology

December 2017

Half of the globe was fast asleep then [when it was 3:15pm (PST) on 13th November at Anaheim, California]. I had just completed reading Murakami’s ‘Samsa in love’.

Last Month in Nephrology

November 2017

In this Cochrane review of 11 RCTs involving 29141 diabetics, intensive control of sugars (HbA1c < 7% or FBS <120)  made little or no difference in the renal and patient survival endpoints: doubling of serum creatinine, ESRD or death as compared to the usual control (HbA1c >7 or FBS >120).

Last Month in Nephrology

October 2017

A secondary analysis of SPRINT trial (BTW, how many can be done per trial?), looking at the Effects of Intensive Systolic Blood Pressure Control on Kidney and Cardiovascular Outcomes in Persons Without Kidney Disease is published in Annals of Internal Medicine.

Last Month in Nephrology

September 2017

2017 update on AKI prevention by Working Group on Prevention, AKI section, European Society of Intensive Care Medicine is here.

Last Month in Nephrology

August 2017

TESTING  was a multicenter, double-blind, randomized clinical trial which planned to enroll 750 participants with IgA nephropathy (proteinuria greater than 1 g/d and estimated glomerular filtration rate [eGFR] of 20 to 120 mL/min/1.73 m2) after at least 3 months of blood pressure control with renin-angiotensin system blockade.

Last Month in Nephrology

July 2017

Urinary creatinine clearance 59 ml/min, DTPA GFR  75 ml (gates), 65 ml (plasma sampling), CKD-EPI 90 ml/min, CKD-EPI using cystatin C 102 ml/min–these are ‘GFR’ values by various methods for one of our perfectly healthy 58-year-old donor under evaluation.

Last Month in Nephrology

June 2017

RCT in Nephrology is that rare occasion to celebrate especially if it is positive. Here is a multi-centre, double-blind, placebo-controlled trial (NEFIGAN) of Targeted-release formulation ((TRF) budesonide versus placebo in patients with IgA nephropathy.

Last Month in Nephrology

April – May 2017

In this JASN study, 105 pregnancies classified as rAKI (pregnant women with history of recovered AKI) were compared with 24640 control pregnancies-authors noted that “past episode of AKI, despite return to normal renal function before pregnancy, associated with maternal adverse outcomes in pregnancy”.